other material
confidence high
sentiment positive
materiality 0.85
Elicio reports 3 complete responses post-ELI-002 7P with checkpoint inhibition in mPDAC
Elicio Therapeutics, Inc.
- 100% confirmed complete radiographic and metabolic responses in 3 patients who progressed on ELI-002 7P and received nivolumab-based therapy.
- Complete responses rarely observed (0-8%) in metastatic pancreatic cancer; all 3 patients are MSS/MMR-p, historically refractory to immunotherapy.
- Two patients maintained complete responses ≥8 months; one ongoing >13 months with persistent mKRAS-specific T cells.
- Elicio plans Phase 1 study in first-line metastatic mKRAS PDAC combining ELI-002 7P with chemotherapy and anti-PD-1, subject to funding.
- Virtual KOL event June 24, 2026, to discuss observations with UCLA and University of Miami oncologists.